More Insurers Willing to Cover Whole Exome Sequencing (WES) in a Trend That Creates New Opportunities for Clinical Pathology Laboratories to Add Value

Most insurers still determine coverage on a case-by-case basis, but two major payers now have coverage policies that are helpful to clinical labs that perform WES Whole exome sequencing (WES) is not new for clinical pathologists, but it is becoming more common in a clinical setting as more physicians learn about its uses. This is due to two reasons. First, researchers are identifying new ways to use whole exome sequencing to improve patient care. Second, the cost of whole genome sequencing...

China Puts the Kibosh on Genetic Testing, Surprising Even Genetic Experts—Effects on Recent Multi-million Dollar Investment by BGI of Shenzhen Uncertain

Prenatal testing, the most popular in China, is banned, affecting current projects at providers—another lesson for laboratories in how quickly things change Genetic testing has been halted in China. This unexpected decree was announced in February. Government officials cited challenges surrounding “ethics, privacy, and the protection of human heredity resources, in a message posted on the China Food and Drug Administration’s website. Authorities named prenatal DNA tests in particular as an...
;